Gene Patenting, the Supreme Court’s Myriad Decision, and the Future of Biotechnology image

September 23, 2013 4:00 PM
Lectures and Panels
2013-2014
Austin 100, Harvard Law School
1515 Massachusetts Ave. , Cambridge, MA

Moderated by Dean Martha Minow of Harvard Law School, this panel will focus on the impact of the Supreme Court's recent decision in the Myriad case that naturally occurring DNA cannot be patented. Will this be a boon for patients and a burden for biotech companies? Will sufficient incentive remain for innovation?  Will there be any practical change at all? Panelists will include:

  • Eric S. Lander, Director of the Broad Institute of MIT and Harvard, Professor of Biology at MIT, and Professor of Systems Biology at Harvard Medical School

  • I. Glenn Cohen, Professor of Law, Harvard Law School; Faculty Co-Director of the Petrie-Flom Center

  • Benjamin N. Roin, Hieken Assistant Professor in Patent Law, Harvard Law School; Faculty Co-Director of the Petrie-Flom Center

  • Claire Laporte, Partner, Foley Hoag LLP

  • Tania Simoncelli, former Science Advisor to the ACLU

Co-sponsored by the Broad Institute of MIT and Harvard.

Watch the full event online here

Tags

benjamin n. roin   biotechnology   genetics   health law policy   i. glenn cohen   judicial opinions